Anthropic has established a physical laboratory in the San Francisco Bay Area to carry out wet lab operations alongside its computer modeling work, according to an investigation published by Reuters on September 18, 2026. The move expands the startup’s capabilities from purely computational, “in silico” predictions to physical experimentation.
While the presence of an in-house facility marks a tangible evolution in Anthropic’s technical infrastructure, the company maintains a specific operational scope. A corporate spokesperson clarified that the lab is not dedicated to direct drug discovery, while Anthropic’s head of life sciences, Eric Kauderer-Abrams, emphasized the necessity of real-world testing. “We believe that to do biology, the final test is still and will be for a while in real lab work,” Kauderer-Abrams stated. “We absolutely are doing that today.”
Bridging Simulation and Laboratory Automation
Computer models are great at predicting protein folding, but software alone can only get you so far when dealing with the unpredictable messiness of real biology. To bridge this gap, Anthropic is combining internal lab testing with external research partnerships, using its own facilities to generate proprietary experimental data that continuously feeds back into Claude.
At the center of the initiative is lab automation. Anthropic is testing how Claude can direct robotic equipment to execute biological protocols with minimal human oversight. To support this integration, the company introduced its open-source Model Hardware Standard in August 2026, creating a unified framework for AI systems to interface with laboratory hardware.
The physical expansion follows significant investments in Anthropic’s life sciences division, which has become one of its largest sectors by headcount and capital allocation. The startup previously acquired Coefficient Bio for approximately $400 million in stock to bolster its biological software suite, and appointed Novartis CEO Vas Narasimhan to its board of directors.
Safety Governance, Commercial Cautions, and Market Friction
The establishment of a physical biology lab occurs alongside Anthropic’s broader emphasis on AI safety research and risk management. As part of its public commitment to responsible development, the company continues to evaluate potential biosecurity vulnerabilities, studying how advanced models might be misused and building internal guardrails to mitigate potential biological risks before deploying new capabilities.
At the same time, Anthropic has to walk a fine line with its big pharma clients. Major pharmaceutical partners, including Genentech, Bristol Myers Squibb, and Novo Nordisk, utilize Anthropic’s infrastructure but remain sensitive to potential data exposure or indirect competition. To address these concerns, Anthropic has explicitly capped its operational boundaries: the company confirms it will not run human clinical trials or bring finished pharmaceutical products to market independently.
What to Watch Next
As Anthropic scales its physical research capabilities, three key variables will determine the impact of the initiative:
Robotic Execution Rates: The measurable efficiency gains delivered by Claude-directed laboratory robotics compared to traditional, human-operated automated workflows.
Pharma Partner Data Isolation: The effectiveness of data-sandboxing policies designed to prevent proprietary client research from overlapping with internal Anthropic projects.
Preclinical Output: Whether automated testing on complex, “undruggable” targets and rare diseases yields viable candidates for licensing to external commercial partners.